Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection - Wikidata - wikimedia - TriplyDB

Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection

Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection

http://www.wikidata.org/entity/Q35865538

about

Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control Animal models of Middle East respiratory syndrome coronavirus infection Searching for animal models and potential target species for emerging pathogens: Experience gained from Middle East respiratory syndrome (MERS) coronavirus Potent and selective inhibition of pathogenic viruses by engineered ubiquitin variants.Molecular aspects of MERS-CoV.MERS-CoV spike protein: a key target for antivirals.A review of treatment modalities for Middle East Respiratory Syndrome.Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia.A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus.Swift antibodies to counter emerging viruses.Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge.Middle East respiratory syndrome coronavirus infection: virus-host cell interactions and implications on pathogenesis Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease Treatment strategies for Middle East respiratory syndrome coronavirus.3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012 Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection.Mapping the Specific Amino Acid Residues That Make Hamster DPP4 Functional as a Receptor for Middle East Respiratory Syndrome Coronavirus Middle East respiratory syndrome vaccines.Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection.CD8+ T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory Syndrome.One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques.Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.Vaccines for Emerging Infectious Diseases: lessons from MERS coronavirus and Zika virus.Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody.Middle East respiratory syndrome and severe acute respiratory syndrome.A Comparative Review of Animal Models of Middle East Respiratory Syndrome Coronavirus Infection.Vaccines for the prevention against the threat of MERS-CoV.Vaccines against Middle East respiratory syndrome coronavirus for humans and camels.Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV).Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection Middle East respiratory syndrome coronavirus: five years later.Permissivity of Dipeptidyl Peptidase 4 Orthologs to Middle East Respiratory Syndrome Coronavirus Is Governed by Glycosylation and Other Complex Determinants.Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice.

P2860

Q26700054-65A0B21A-59FC-4F17-8491-43539C6B9C7C Q26796501-F3AD7CD3-8010-4A17-8710-846587FCDD5D Q28086778-5AA30842-9B76-4ABE-A743-90BA0CCBA7D1 Q28873816-E456BE42-A44A-4AAE-B896-FE09A7586026 Q30145557-7CDE97E1-E8C2-44F5-9013-ACAFE3583EB1 Q30234479-3BB35A1C-61C2-47ED-A949-A702B7201F64 Q30240139-4DFFBFF9-DE08-4C39-804C-B1783EEE9B3F Q30248209-0FD1BBBA-4003-4B8F-8B78-03AF6943ECD8 Q30356651-BE412E6C-D6B0-42A7-B89E-F0AC4DE1E699 Q30379384-B885A741-E1E6-4884-A53E-B9E558F6F2CA Q30402347-1EFB2F56-21A8-4861-81BE-B38774F7EF01 Q33594304-688DD325-400B-4159-AA7A-592A21FC9BFE Q35877765-E9887B09-A510-45EE-9E0D-620D33618157 Q35989719-B75BE523-55DF-4ED2-82F1-8B304AFF5FEA Q36252666-5D77056B-0486-4A6C-BC16-297A7D6220DB Q36393296-9FB645F0-495F-4ECF-B1BA-D7C84F0FB735 Q36433987-B2C1FA63-90D9-47AF-8495-3E968E2D9C94 Q36555622-B505890B-1CAB-47AC-9ED5-AD56D45F0626 Q36626864-8FA4141F-BF64-4568-9FB7-586C77A4204E Q36816625-5056C0D3-5E88-4C20-96A4-E9E6AE540EF9 Q37069816-4B31538D-D7AC-4F16-9788-D75B44A2EDF1 Q37143501-88C52181-2085-460C-8CFF-C939F1D35CDA Q37169882-A81F8626-C078-459C-97CC-29A1FFED6F10 Q37188934-48E8EEB1-2F3D-4BB4-9D1B-236D76954B7A Q37512816-23094793-22FD-474F-9AE5-8307EEC59739 Q37560824-315EDDC6-9F67-42BF-AA19-D8F7A186BD78 Q37706472-2A346A1C-84D5-4673-A7A0-2D077A489AF1 Q37717377-35261497-6560-4204-A218-1EDCFD535D69 Q38156536-E0193F3C-5AA7-4409-A0FC-8AD34D700979 Q38619800-5E711B10-15B8-4EFB-8E00-48739FA9CAC6 Q38725989-EDE4771C-17D8-4662-8F0B-856A85DBAF71 Q38730484-EE8D11CC-ABEA-494F-A75A-F108A142A0FF Q38778044-0C1A7630-630F-449D-ABF3-DF19F7E131B9 Q38992327-41DD252D-FECA-4BE5-B364-F438BD3B44F7 Q39034541-5656F7F3-12E1-4512-A23F-F7E2000C4CF3 Q39279748-26C4866B-6E92-4689-8AE1-12D45BE33B66 Q39677274-FC03623C-9E9A-4811-B681-68759D074136 Q40085786-5294A555-43D7-4F3B-88FC-C5867C05BEED Q40107025-07973505-F12C-46F6-AA73-A2AA8B2624C1 Q40271304-AC3AAC2B-5EA9-473F-B0FD-53001A4A7E3D

P2860

Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection

http://www.wikidata.org/entity/Q35865538

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pre- and postexposure efficacy ...... se model of MERS-CoV infection

@ast

Pre- and postexposure efficacy ...... se model of MERS-CoV infection

@en

type

label

Pre- and postexposure efficacy ...... se model of MERS-CoV infection

@ast

Pre- and postexposure efficacy ...... se model of MERS-CoV infection

@en

prefLabel

Pre- and postexposure efficacy ...... se model of MERS-CoV infection

@ast

Pre- and postexposure efficacy ...... se model of MERS-CoV infection

@en

P1433

Q35865538-99DAF778-D05F-4F5A-8B0D-41058BEAA1FC

P1476

Q35865538-1AEDE989-F963-48CB-8529-5B436A9673D4

P2093

Q35865538-055686B3-1462-4C61-B40D-AD53AD7E761B

Q35865538-088B8237-A2A0-4ACD-B3A5-D38B1D3C1895

Q35865538-177989FF-A449-41F0-A334-ECB6AEB7F614

Q35865538-1A27C62B-61BF-4E34-A1D8-34F3B410BEF2

Q35865538-21F8E06B-6370-4E9D-8BCF-84CED3C1BDA5

Q35865538-44097084-14D6-4D65-A6D7-BB23B35A264D

Q35865538-553E7B8C-C511-4EF9-983A-80A1C76FF17A

Q35865538-55CB98C9-75E8-437C-B808-B9E5F09B92A2

Q35865538-5DE268E0-2E39-45E6-8DBD-020412C89E33

Q35865538-609A9AB9-3A87-4225-9342-E53CA1528FB7

P2860

Q35865538-076FD0B5-CC73-44BB-AE2F-39C41B3D1442

Q35865538-0815D4A6-A4BC-4284-81D1-1A9B27221666

Q35865538-15638842-BE4A-47D2-8555-18AF318785E3

Q35865538-15FEF646-BF3E-443A-B9B5-0C4E06A14CB0

Q35865538-18FC1BCA-01CF-4458-9FD6-91AA66AE499B

Q35865538-203A9FC8-59ED-4ECD-8EBC-E18A9D26AA70

Q35865538-28EEED7F-448E-4C1F-92B9-E04A858FA745

Q35865538-39EA1B71-A3B6-4A53-AFF8-114F9B20C016

Q35865538-4ACE5EC2-8642-476C-9623-49240F8FA2F8

Q35865538-53B562B1-7E3E-4A5B-983B-EB8E3C7CE587

P304

Q35865538-612A25BC-ACBF-4EFC-A772-30E6AD7DFCB1

P31

Q35865538-CC6B584E-CFDC-434B-A833-BD9FDC0D7F1B

P356

Q35865538-C4AC4310-9357-4EA6-B54B-4F4DEE1C2EDC

P407

Q35865538-5B8D45D4-D30F-4A0E-8ADC-2195CC8A12B8

P433

Q35865538-09457263-73A4-49FC-8F39-7123ED92A687

P478

Q35865538-0B66A7A6-FC60-4CF4-A07D-637F9E8AF6B3

P50

Q35865538-B09E20A1-00AF-4F99-8EE7-2D58C525F6FB

Q35865538-E34639C6-EE83-4408-9A26-C1A177F5682F

P577

Q35865538-98FF9122-E132-498F-9214-BC7931C0BD7E

P5875

Q35865538-EC572501-4A26-4991-BD91-B3E9630B1F39

P698

Q35865538-F44148C7-BA72-44E7-B78B-AE7C7DCDD92E

P921

Q35865538-20B7E2B3-1029-491B-9857-8934158697A3

Q35865538-5D3ED83A-4CF3-458B-A09A-2FAEB759895E

P932

Q35865538-FC7AB040-4B50-461F-A13B-6A77F3A82C3C

P356

PNAS.1510830112

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Pre- and postexposure efficacy ...... se model of MERS-CoV infection

@en

P2093

Alejandro O Mujica

http://www.w3.org/2001/XMLSchema#string

Alexander Berrebi

http://www.w3.org/2001/XMLSchema#string

Ashok Badithe

http://www.w3.org/2001/XMLSchema#string

Charleen Hunt

http://www.w3.org/2001/XMLSchema#string

Christos A Kyratsous

http://www.w3.org/2001/XMLSchema#string

Gang Chen

http://www.w3.org/2001/XMLSchema#string

George D Yancopoulos

http://www.w3.org/2001/XMLSchema#string

Jeanette Fairhurst

http://www.w3.org/2001/XMLSchema#string

Jeanne M Sisk

http://www.w3.org/2001/XMLSchema#string

John Strein

http://www.w3.org/2001/XMLSchema#string

P2860

Infection with MERS-CoV causes lethal pneumonia in the common marmoset

Emergence of the Middle East respiratory syndrome coronavirus

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4

High-throughput engineering of the mouse genome coupled with high-resolution expression analysis

Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Rapid generation of a mouse model for Middle East respiratory syndrome.

Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

P304

8738-8743

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1510830112

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Christopher Coleman

Kristen E Pascal

P577

2015-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280032118

http://www.w3.org/2001/XMLSchema#string

P698

26124093

http://www.w3.org/2001/XMLSchema#string

P921

Middle East respiratory syndrome coronavirus

P932

4507189

http://www.w3.org/2001/XMLSchema#string